Cladribine (Mavenclad): MS Clinical Trials
7 active trials · 1 recruiting
7 active multiple sclerosis clinical trials involve Cladribine (Mavenclad), 1 currently recruiting. The list is matched on the interventions registered at ClinicalTrials.gov, so it includes head-to-head comparisons and studies where this therapy is the comparator as well as the treatment under test.
Trial results are not treatment advice: whether a therapy is right for you depends on your type of MS, disease activity and history, which is a conversation for your neurologist.
Active Cladribine (Mavenclad) MS trials
RecruitingPhase 2
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
Sponsor: Institute of Psychiatry and Neurology, Warsaw
Cladribine Subcutaneous Injection · 0.9% Chloride Injection Sodium
188 participantsDetails ›
By invitation only
Relationship Between Oral DMT Burden and Adherence in MS
Sponsor: Monash University
Cladribine · Dimethyl fumarate
323 participantsDetails ›
Closed to new patients
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Mavenclad
367 participantsDetails ›
Closed to new patientsPhase 4
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
Sponsor: University of Texas Southwestern Medical Center
Cladribine
2 states40 participantsDetails ›
Closed to new patientsNA
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Sponsor: Johns Hopkins University
Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…
28 states900 participantsDetails ›
Closed to new patientsPhase 2
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
Sponsor: Queen Mary University of London
Cladribine (MAVENCLAD®) · Placebo
204 participantsDetails ›
Closed to new patientsPhase 3
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
Sponsor: Haukeland University Hospital
Cyclophosphamide and ATG · Alemtuzumab
100 participantsDetails ›
MS trials by therapy
Exercise and rehabilitation (81)Ocrelizumab (Ocrevus) (34)Ofatumumab (Kesimpta) (18)Diet and nutrition (12)Teriflunomide (Aubagio) (9)Fingolimod (Gilenya) (8)Ublituximab (Briumvi) (7)Rituximab (6)Ozanimod (Zeposia) (6)Dimethyl fumarate (Tecfidera) (6)Interferon beta (5)Fenebrutinib (5)Stem cell therapy (aHSCT and MSC) (5)Natalizumab (Tysabri) (4)Siponimod (Mayzent) (4)Remibrutinib (4)CAR-T cell therapy (4)Alemtuzumab (Lemtrada) (3)Glatiramer acetate (Copaxone) (3)Frexalimab (3)Metformin (3)Cannabis and cannabinoids (3)
The app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.